Embolization: Blocking Blood Vessels to Treat Disease

Embolization is a minimally invasive interventional radiology procedure that deliberately obstructs blood flow through targeted vessels to treat a range of conditions — from tumors and arteriovenous malformations to hemorrhage and uterine fibroids. The procedure is performed by interventional radiologists using image guidance and specialized catheters threaded through the vascular system. This page covers the definition and scope of embolization, the mechanism by which it works, the clinical scenarios where it is applied, and the decision boundaries that determine when it is appropriate versus when other treatments are preferred.

Definition and scope

Embolization describes any procedure in which an occluding agent is intentionally delivered into a blood vessel to block flow to a specific target tissue. The term encompasses dozens of distinct clinical applications unified by a single mechanical principle: reducing or eliminating perfusion to a site where blood supply is driving disease.

The interventional radiology field broadly classifies embolization procedures by the size of the vessel targeted, the type of occluding material used, and the intended permanence of the occlusion. Major categories include:

According to the Society of Interventional Radiology (SIR), embolization procedures number in the hundreds of thousands annually across US facilities, reflecting the breadth of conditions addressable without open surgery.

The regulatory context for radiology, including Centers for Medicare & Medicaid Services (CMS) coverage determinations and FDA device clearances for embolic agents, directly governs which materials and indications carry reimbursement or market authorization in the United States.

How it works

All embolization procedures follow a structured sequence grounded in real-time imaging guidance:

  1. Vascular access — A hollow needle punctures a peripheral artery or vein, most commonly the common femoral artery in the groin or the radial artery at the wrist. A sheath is placed over a guidewire to maintain access.
  2. Catheter navigation — A flexible catheter is advanced under fluoroscopic or digital subtraction angiography (DSA) guidance through the vasculature to the target vessel. Microcatheters with outer diameters as small as 1.8 French (approximately 0.6 mm) allow access to distal or tortuous vessels.
  3. Diagnostic angiography — Contrast material is injected to map the target anatomy, confirm catheter position, and identify collateral supply routes before any occluding agent is delivered. The principles governing contrast agent selection and risk apply fully at this stage.
  4. Embolic delivery — The chosen occluding agent is injected through the catheter. The interventional radiologist monitors flow cessation fluoroscopically in real time.
  5. Completion angiography — A final contrast run confirms the intended degree of occlusion and identifies any untreated collateral feeding vessels.
  6. Access closure — The catheter and sheath are removed, and hemostasis is achieved by manual compression or a vascular closure device.

The embolic agents themselves fall into three structural categories:

The intended permanence of occlusion is a defining variable. Gelatin sponge (Gelfoam) produces temporary occlusion over days to weeks, while metallic coils and calibrated microspheres produce permanent vessel closure.

Common scenarios

Embolization addresses four principal clinical problem categories:

Hemorrhage control — Arterial embolization is a first-line intervention for gastrointestinal bleeding unresponsive to endoscopy, traumatic solid organ injury (liver, spleen, kidney), postpartum hemorrhage, and epistaxis refractory to packing. Embolization avoids general anesthesia in critically unstable patients.

Tumor treatment — TACE is the most widely studied embolic oncologic technique. The American Association for the Study of Liver Diseases (AASLD) guidelines identify TACE as a standard-of-care option for intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage B). Radioembolization using yttrium-90 microspheres extends the tumor-directed approach by combining embolization with internal radiation.

Uterine fibroids — Uterine fibroid embolization is an alternative to hysterectomy or myomectomy for women with symptomatic fibroids. Published literature documents fibroid volume reduction of 40–60% at 6 months post-procedure, with symptom relief reported in approximately 85–90% of appropriately selected patients (SIR patient education resources).

Vascular malformations — Cerebral AVM embolization performed before surgical resection or stereotactic radiosurgery reduces operative blood loss and allows safer access to the nidus. Interventional neuroradiologists subspecializing in this domain complete dedicated interventional radiology fellowship training.

Decision boundaries

Embolization is selected over open surgical or ablative alternatives based on four intersecting factors:

Anatomic accessibility — A vessel must be selectively catheterizable without crossing critical non-target anatomy. Highly tortuous or severely diseased iliac vessels can preclude femoral access; radial access or direct puncture may be substituted.

Target tissue characteristics — Tumors with dual blood supply (hepatic artery and portal vein, as in liver metastases from colorectal cancer) present incomplete occlusion risk; the portal venous contribution limits the efficacy of arterial-only embolization.

Patient reserve — Patients with Child-Pugh class C cirrhosis face hepatic decompensation risk from TACE because the occluded hepatic arterial supply is disproportionately critical to the compromised liver. The AASLD and European Association for the Study of the Liver (EASL) both define contraindications based on liver function scoring.

Occlusion permanence requirement — Temporary gelatin sponge embolization is appropriate when re-establishment of flow is desirable (e.g., prophylactic embolization before a planned surgical procedure). Permanent coil or plug occlusion is used when ongoing flow would perpetuate disease.

Embolization is distinct from radiofrequency ablation, which destroys tissue using thermal energy rather than ischemia, and from angiography and vascular interventions that restore rather than obstruct flow. The choice between ischemia-based and ablation-based strategies depends on tumor size, location relative to biliary or vascular structures, and available operator expertise.

The FDA regulates embolic devices under 21 CFR Part 870 (cardiovascular devices) and issues 510(k) clearances for new embolic microsphere formulations through the Center for Devices and Radiological Health (CDRH). CMS reimbursement for embolization procedures is assigned under Current Procedural Terminology (CPT) codes in the 37200 series for vascular embolization and occlusion, with specific codes differentiating arterial, venous, and intracranial applications.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)